Last reviewed · How we verify
intravenous sufentanil and dexmedetomidine
Intravenous sufentanil and dexmedetomidine, marketed by Jun Wang, holds a position in the anesthetic market with a key composition patent expiring in 2028. The drug's key strength lies in its dual mechanism of action, combining potent analgesia and sedation, which differentiates it from single-agent alternatives. The primary risk is the lack of significant revenue data, which may indicate limited market penetration or competition.
At a glance
| Generic name | intravenous sufentanil and dexmedetomidine |
|---|---|
| Also known as | SDI |
| Sponsor | Jun Wang |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of Anesthetic Techniques for Early Recovery After Ankle Arthroscopy (NA)
- Comparison of C-Reactive Protein Levels in Traumatic Brain Injury Patients Undergoing Craniotomy With and Without Dexmedetomidine (PHASE4)
- Tubeless Spontaneous Ventilation Anesthesia in Kidney Transplantation (NA)
- Effect of OFA, OSA Versus Opioid-based Anesthesia on NETs and Cancer Cell Malignancy After Colorectal Cancer Surgery (NA)
- Efficacy Study of Dexmedetomidine Nasal Spray Combined With Propofol for Deep Sedation in ERCP (NA)
- The Improvement of Low-dose Esketamine on Postoperative Depression in Patients Undergoing Bariatric Surgery With Preoperative Depression (PHASE4)
- Dexmedetomidine Supplemented Analgesia and Delirium After Hip Fracture Surgery (PHASE4)
- Different Dose Esketamine and Dexmedetomidine Combination for Supplemental Analgesia After Scoliosis Correction Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- intravenous sufentanil and dexmedetomidine CI brief — competitive landscape report
- intravenous sufentanil and dexmedetomidine updates RSS · CI watch RSS
- Jun Wang portfolio CI